<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HD83BE4C78A5044C388428FD5247F22AF" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 406 IH: Combination Drug Development Incentive Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-01-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 406</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150120">January 20, 2015</action-date>
			<action-desc><sponsor name-id="C001076">Mr. Chaffetz</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend section 505 of the Federal Food, Drug, and Cosmetic Act to provide incentives for the
			 development of new combination drugs.</official-title>
	</form>
	<legis-body id="HA27363A1E45C429AAD86162EB7F0C576" style="OLC">
 <section id="H1B66DB6187604B84B337759CA2E31020" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Combination Drug Development Incentive Act of 2015</short-title></quote> .</text> </section><section id="H4B440EDF22E54DCF83712828EBF5C205"><enum>2.</enum><header>Applicability to combination drugs submitted under a new drug application</header> <subsection id="H15E4DBC4001043EFBDA0C70B567E0FE5"><enum>(a)</enum><header>In general</header><text>Clause (ii) of section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)(3)(E)(ii)</external-xref>) is amended—</text>
 <paragraph id="H82AF9945D6B546A7B824E71ADDD9F0B2"><enum>(1)</enum><text>by striking <quote>(ii) If an application submitted under subsection (b) for a drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under subsection (b),</quote> and inserting <quote>(ii)(I) If an application submitted under subsection (b) for a drug, and described in subclause (II) or (III),</quote>; and</text>
 </paragraph><paragraph id="HAEB797A0EA144924B6373630D369ECD8"><enum>(2)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H0235E249EA924DECBC655195A8B34598" style="OLC"> <subclause id="HBA1370B47FF24F658FD354FAB9E728BF" indent="up3"><enum>(II)</enum><text display-inline="yes-display-inline">An application is described in this subclause if no active ingredient (including any ester or salt of the active ingredient) of the drug for which the application has been submitted has been approved in any other application under subsection (b).</text>
 </subclause><subclause id="H0A6D360CA81840169F4E16DAC17CF56B" indent="up3"><enum>(III)</enum><text display-inline="yes-display-inline">An application is described in this subclause if—</text> <item id="H1B4E0C43B57C44B28F0FBD9FC46A69D5"><enum>(aa)</enum><text>the application contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant;</text>
 </item><item id="H0286CFFEB1D147348BF87AF9572EF02D"><enum>(bb)</enum><text>the application is for a drug which contains a combination of active ingredients; and</text> </item><item id="H886F602306684426A5D0AFDD20301339"><enum>(cc)</enum><text>no such combination of active ingredients has been approved in any other application under subsection (b).</text></item></subclause><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="HF940D60ACC7342318619BE405168BFD6"><enum>(b)</enum><header>Applicability</header><text>Subclause (I) of section 505(c)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act, as designated by subsection (a)(1), is amended by striking <quote>is approved after the date of the enactment of this clause</quote> and inserting <quote>is approved after January 1, 2016, in the case of an application described in subclause (II) or subclause (III)</quote>.</text>
 </subsection><subsection id="HC527DC91C8604B198D29883EFDCAD075"><enum>(c)</enum><header>Conforming amendment</header><text>Clause (iii) of section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)(3)(E)</external-xref>) is amended by striking <quote>If</quote> and inserting <quote>Except as provided in clause (ii), if</quote>.</text>
			</subsection></section><section id="H67BEEA0CD55947AB99EBCD98A2881FD0"><enum>3.</enum><header>Applicability to combination drugs submitted under an abbreviated new drug application</header>
 <subsection id="H538C81A6011F4AED9D899AD3243D0578"><enum>(a)</enum><header>In general</header><text>Clause (ii) of section 505(j)(5)(F) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(F)</external-xref>) is amended—</text>
 <paragraph id="HB0CE68EF71AC481F8CE8E3E71EC1C8DF"><enum>(1)</enum><text>by striking <quote>(ii) If an application submitted under subsection (b) for a drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under subsection (b),</quote> and inserting <quote>(ii)(I) If an application submitted under subsection (b) for a drug, and described in subclause (II) or (III),</quote>; and</text>
 </paragraph><paragraph id="H66C35CCE230448349476EDE107A04B87"><enum>(2)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H7CDE5DBA38634C9FAE5B2841AC11174A" style="OLC"> <subclause id="HAC8DC53BE8F14009B243710D2A6FFAAE" indent="up4"><enum>(II)</enum><text display-inline="yes-display-inline">An application is described in this subclause if no active ingredient (including any ester or salt of the active ingredient) of the drug for which the application has been submitted has been approved in any other application under subsection (b).</text>
 </subclause><subclause id="H474B0C94CB13428EAA6F4C55C04DFE94" indent="up4"><enum>(III)</enum><text display-inline="yes-display-inline">An application is described in this subclause if—</text> <item id="H1C269A0A7B294E34A03FB58BA3F5436C"><enum>(aa)</enum><text>the application contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant;</text>
 </item><item id="H47ED777A4C004243B6EB8602D77233B3"><enum>(bb)</enum><text>the application is for a drug which contains a combination of active ingredients; and</text> </item><item id="H5BC44F2DFE73475484E985C188BA41C9"><enum>(cc)</enum><text>no such combination of active ingredients has been approved in any other application under subsection (b).</text></item></subclause><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="HA839C0B86B534C67AF51F5C5A3BF8D2A"><enum>(b)</enum><header>Applicability</header><text display-inline="yes-display-inline">Subclause (I) of section 505(j)(5)(F) of the Federal Food, Drug, and Cosmetic Act, as designated by subsection (a)(1), is amended by striking <quote>is approved after the date of the enactment of this subsection</quote> and inserting <quote>is approved after January 1, 2016, in the case of an application described in subclause (II) or subclause (III)</quote>.</text>
 </subsection><subsection id="HEAFDB33834CA49659C328D25C734ADA7"><enum>(c)</enum><header>Conforming amendment</header><text>Clause (iii) of section 505(j)(5)(F) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(F)</external-xref>) is amended by striking <quote>If</quote> and inserting <quote>Except as provided in clause (ii), if</quote>.</text>
			</subsection></section></legis-body>
</bill>


